

Molecular characteristics of recurrent triple-negative breast cancer

CHUNG-HSIN TSAI^{1,2}, JEN-HWEY CHIU^{1,3,4}, CHU-WEN YANG⁵, JIR-YOU WANG⁶,
YI-FANG TSAI³, LING-MING TSENG^{3,7}, WEI-SHONG CHEN^{8,9} and YI-MING SHYR³

¹Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei 112; ²Division of General Surgery, Department of Surgery, Mackay Memorial Hospital, Taipei 251; ³Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112; ⁴Division of General Surgery, Department of Surgery, Cheng-Hsin General Hospital, Taipei 112; ⁵Department of Microbiology, Soochow University, Taipei 111; ⁶Department of Orthopedics, Taipei Veterans General Hospital, Taipei 112; ⁷Department of Surgery, School of Medicine, National Yang-Ming University, Taipei 112; ⁸Division of Colorectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112; ⁹Experimental Surgery of the Department of Surgery, Taipei Veterans General Hospital, Taipei 112, Taiwan, R.O.C.

Received January 28, 2014; Accepted May 28, 2015

DOI: 10.3892/mmr.2015.4360

Abstract. Due to the fact that the treatment of breast cancer depends significantly on the molecular markers present in the cancer, including estrogen receptor (+), progesterone receptor (+) or erbB2 receptor (+), further investigation targeting triple-negative breast cancer (TNBC) subtypes may assist in elucidating the mechanisms of recurrence of TNBC and enable the identification of novel therapeutic strategies for patients with TNBC. The aim of the present study was to compare the gene expression profiles between TNBC samples that were identified as having recurrent and non-recurrent statuses. Between June 2011 and May 2012, a total of 30 patients with TNBC were examined using a follow-up period of at least 5 years. Their clinicopathological information was retrospectively reviewed and they were classified with a status either of recurrence [n=15 stage II (9), IIIA (2), IIIC (4)] or non-recurrence [n=15 stage II (6), IIIA (1), IIIC (8)]. The total RNA from tissue samples obtained from the recurrent and non-recurrent TNBC patients were used to performed oligonucleotide microarray analysis. The dataset was analyzed using GeneSpring software and validated using reverse transcription-quantitative polymerase chain reaction. Principal component analysis demonstrated that there was a marked difference in the gene expression distribution between

the stage IIIC recurrent samples and early stage (stages IIA, IIB and IIIA) recurrent samples. In early stage recurrence, the significant pathway-associated upregulated genes were matrix metalloproteinases (MMPs) and genes associated with cancer cell migration (CDH2) and cell adhesion/motility (KRAS, CDC42, RAC1, ICAM and SRGAP2). By contrast, during stage IIIC recurrence, the significant pathway-associated upregulated genes in the recurrent samples were WNT signaling genes, including WNT 4 and WNT 16. It was concluded that there were markedly different distributions and gene expression profiles between stage IIIC recurrent TNBC tumors and early stage (IIA, IIB, IIIA) recurrent TNBC tumors, which provides important information for the development of effective treatment strategies for TNBC.

Introduction

Breast cancer is the most common type of invasive cancer in females worldwide (1,2). In addition to conventional prognostic factors, including tumor size, lymph node status, estrogen receptor (ER)/progesterone receptor (PR) status, erbB2 receptor (HER2) status, several other biological markers, including Ki67, tau and topo II, have been investigated in order to correlate their status with the prognosis of patients with breast cancer (3,4). Due to a lack of specific receptors, triple-negative (ER-, PR-, HER2-) breast cancer (TNBC) exhibits marked resistance to chemotherapy, hormone therapy and targeted therapy (5-7). The subtype comprises ~15% of all cases of breast cancer and results in tumors, which are typically larger in size and higher in grade, compared with other types of breast cancer.

The identification of intrinsic subtypes of breast cancer has provided a number of novel therapeutic targets and enabled the design of novel clinical trials (8). Due to the lack of specific therapeutic targets with TNBC, previous studies have aimed to identify novel molecular markers, including

Correspondence to: Dr Ling-Ming Tseng, Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, 201, Sec. II Shih-Pei Road, Shih-Pei, Taipei 11217, Taiwan, R.O.C.
E-mail: lmtseng@vghtpe.gov.tw

Key words: breast cancer, triple-negative, subtype, gene expression, microarray

phosphoinositide 3-kinase, epidermal growth factor receptor (EGFR), cell-cycle regulatory proteins, heat shock proteins, epigenetic pathways and androgen receptors, and clinical trials have been performed (8,9). In this context, the loss of androgen receptor expression has been found to predict early recurrence in triple-negative and basal-like breast cancer (10). However, the therapeutic outcomes have not reached initial expectations.

Previous genome-wide association investigations have identified genetic variants, which are associated with an increased risk of developing breast cancer. Furthermore, gene expression profile analyses have provided multi-gene signatures associated with TNBC carcinogenesis (11,12). Although investigations are increasingly focussing on the recurrence (5,6,13) and treatment (7) of TNBC, the molecular profiles of paired specimens obtained from patients with and without subsequent recurrence require further investigation. Therefore, the aim of the present study was to investigate and compare the gene expression profiles obtained from patients with TNBC, with and without recurrent status.

Patients and methods

Human TNBC tissue samples. In the present study, 30 patients, who had been diagnosed with TNBC based on pathological confirmation (ER <1%; PR <1%; HER2, not amplified) and who had been followed up for ≥ 5 years were recruited between June 2011 and May 2012. The tumor stage of these patients was determined using the American Joint Committee on Cancer TNM system (version 6; Springer, Inc., New York, NY, USA). The clinicopathological information was retrospectively reviewed and identified as either recurrent [n=15, stage II (9), IIIA (2), IIIC (4)] or non-recurrent [n=15, stage II (6), IIIA (1), IIIC (8)] at the end of the investigation period (2011-2012). Subsequent to obtaining informed consent from the patients, tumor specimens were obtained during surgery and were stored in liquid nitrogen under the regulations of Taipei Veterans General Hospital (Taipei, China). The present study was approved by the institutional review board of the hospital (2011-06-001GCF; Taipei, China) for microarray gene expression profiling analysis. The tumor tissues were divided into two groups; the recurrent group, defined as the patients being having a recurrence status years later, and the non-recurrent group, defined as those without recurrence at the end of the investigation.

Isolation of RNA from tumor tissues and oligonucleotide microarray analysis. Total RNA was isolated using a modified single-step guanidinium thiocyanate method (TRIzol reagent; cat. no. T-9424; Sigma-Aldrich, St. Louis, MO, USA). The concentration of total RNA required for oligonucleotide microarray analysis was ≥ 0.6 g/l with a quality ratio ≥ 1.8 for absorbance at 260/280 nm and 260/230 nm using a NanoDrop 1000 (Thermo Fisher Scientific, Pittsburgh, PA, USA). Suitable RNA samples were then sent to Genome Research Center, National Yang-Ming University (Taiwan, China), for analysis with the human Affymetrix expression set, Hu-133 2.0 (Affymetrix, Inc., Santa Clara, CA, USA). The dataset obtained was analyzed following normalization against the global signal. The relative expression levels for each gene were obtained using GeneSpring software (GeneSpring GX 11.5; Agilent Technologies, Inc.,




Figure 1. Experimental protocols. TNBC, triple-negative breast cancer; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

Santa Clara, CA, USA) and further pathway analysis using Ingenuity Pathway Analysis software (IPA; Qiagen, Redwood City, CA, USA).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Following extraction of tumor total RNA, complementary DNA (cDNA) was created using a First Strand cDNA Synthesis kit (Invitrogen Life Technologies, CA, USA). TaqMan® Gene Expression Assays (Invitrogen Life Technologies) were then used to validate the differential expression at the mRNA level of various identified genes, such as MMP9 and SERPINE1 set in the recurrent and non-recurrent TNBC samples. The TaqMan system is supported by a well established primer database, which significantly reduces experimental failure due to inappropriate primer design (Invitrogen Life Technologies). All samples were analyzed in triplicate.

Statistical analysis. Analysis of the microarray dataset was divided into three steps. Firstly, the differentially expressed genes were identified using Student's t-test and a repeated measures one-way analysis of variance. The purpose of this step was to identify a gene set associated with recurrent TNBC and with the various cancer grades. Secondly, clustering analysis was performed to validate the performance of the identified gene set, through separation of the different cancer groups, namely recurrent, vs. non-recurrent TNBCs and grade 1, vs. grade 2, vs. grade 3. The purpose of this step was to reduce the number of gene sets originally obtained and to obtain gene sets, which were optimal for cancer subtype classification. The final step was gene set annotation using GeneSpring software and IPA. Gene, Gene Ontology and pathway information were integrated in order to evaluate the biomedical importance of the identified gene sets.

Results

Clinical and pathological information, which was obtained by retrospective review completed at the end of 2012, resulted in two groups of patients, which were divided into those with

Table I. Significant pathways associated with upregulated genes in early ^astage recurrent triple-negative breast cancer.

Pathway	P-value
Hs_Osteoblast_Signaling_WP322_53892	0.00118489
Hs_Endochondral_Ossification_WP474_45241	0.00172066
Hs_Serotonin_Receptor_2_and_ELK-SRF-GATA4_signaling_WP732_49572	0.00175804
Hs_GPCRs_Other_WP117_45343	0.00466699
Hs_Spinal_Cord_Injury_WP2431_56064	0.00606436
Hs_Monoamine_GPCRs_WP58_48221	0.00656731
Hs_Integrated_Cancer_pathway_WP1971_44858	0.00777973
Hs_Prostate_Cancer_WP2263_54728	0.00807849
Hs_Serotonin_Receptor_2_and_STAT3_Signaling_WP733_45035	0.01460303
Hs_EGF-EGFR_Signaling_Pathway_WP437_47973	0.01537961
Hs_RANKL-RANK_Signaling_Pathway_WP2018_48442	0.01752249
Hs_MAP_kinase_cascade_WP1844_44888	0.01822052
Hs_Myometrial_Relaxation_and_Contraction_Pathways_WP289_45373	0.01972625
Hs_SIDS_Susceptibility_Pathways_WP706_55364	0.02248320
Hs_Oncostatin_M_Signaling_Pathway_WP2374_54418	0.02260932
Hs_Glial_Cell_Differentiation_WP2276_53125	0.02541592
Hs_Heme_Biosynthesis_WP561_45350	0.03255886
Hs_Apoptosis_Modulation_and_Signaling_WP1772_44957	0.03513467
Hs_APC-C-mediated_degradation_of_cell_cycle_proteins_WP1782_44955	0.03611077

^aEarly stage was defined as stages IIa, IIb and IIIa.

subsequent recurrence [n=15, stage II (9), IIIA (2), IIIC (4)] and those without recurrence [n=15, stage II (6), IIIA (1), IIIC (8)], as shown in Fig. 1.

Hierarchical clustering analysis of 30 patients with triple-negative breast cancer. A microarray dataset of the 30 TNBC samples was collected and a total 54,675 genes were eligible for analysis. Gene expression data were normalized against normal tissue controls using quantile normalization. The molecular characteristics of the TNBC were investigated at the mRNA level, according to previously described criteria (8). Hierarchical clustering analysis of the 30 TNBC samples, of which 15 were non-recurrent and 15 were recurrent, was performed to identify genes that were upregulated by ≥ 2 -fold. The results demonstrated no significant clustering among the non-recurrent and recurrent samples (data not shown).

Principal component analysis of 15 patients with recurrent triple-negative breast cancer. To investigate the level of heterogeneity within the recurrent tumor samples, principal component analysis was performed and the results demonstrated a marked difference in distribution between the stage IIIC recurrent samples and the early stage (stage IIa, IIb, IIIa) recurrent samples (Fig. 2). The results suggested that the gene expression profiles of the stage IIIC TNBC tumors were different from those of the early stage TNBC tumors, and they were also different from those of the stage IV, metastatic tumors (data not shown).

A number of significant pathways involving specific genes were either upregulated or downregulated during the early




Figure 2. Principal component analysis of 15 recurrent triple-negative breast cancer samples. To investigate heterogeneity in the recurrent tumor samples, principal component analysis was performed with GeneSpring software. The results revealed that there was a markedly different distribution between the stage IIIC samples and the stage IIa, IIb and IIIa recurrent samples.

stages of recurrent TNBC. For validation of the microarray information, RT-qPCR was performed on selected genes, including MMP9 (Fig. 3A) and SERPINE1 (Fig. 3B).

Using bioinformatics software analysis, the 30 TNBC samples were further stratified into four subgroups depending on stage, classified as early stage (IIa, IIb, IIIa) or stage IIIC, and recurrence, classified as non-recurrent or recurrent. In early stage recurrence, the significant pathways with upregu-

Table II. Significant pathways associated with downregulated genes in early stage^a recurrent triple-negative breast cancer.

Pathway	P-value
Hs_Calcium_Regulation_in_the_Cardiac_Cell_WP536_44983	7.37E-05
Hs_Biogenic_Amine_Synthesis_WP550_44978	3.17E-04
Hs_Regulation_of_Actin_Cytoskeleton_WP51_49262	3.96E-04
Hs_Regulation_of_beta-cell_development_WP1897_45053	5.57E-04
Hs_Myometrial_Relaxation_and_Contraction_Pathways_WP289_45373	5.90E-04
Hs_G_Protein_Signaling_Pathways_WP35_45294	0.00159171
Hs_Neural_Crest_Differentiation_WP2064_47071	0.00229661
Hs_Hypothetical_Network_for_Drug_Addiction_WP666_45365	0.00281034
Hs_Benzo(a)pyrene_metabolism_WP696_44980	0.00286947
Hs_Inflammatory_Response_Pathway_WP453_41201	0.00308023
Hs_Selenium_Pathway_WP15_56489	0.00656218
Hs_Osteoblast_Signaling_WP322_53892	0.00703770
Hs_Insulin_Synthesis_and_Processing_WP1830_44856	0.00703770
Hs_Tryptophan_metabolism_WP465_45056	0.00858096
Hs_Estrogen_signaling_pathway_WP712_48214	0.01417347
Hs_SIDS_Susceptibility_Pathways_WP706_55364	0.01731102
Hs_EPO_Receptor_Signaling_WP581_41162	0.02338902
Hs_miRs_in_Muscle_Cell_Differentiation_WP2012_45377	0.03248199
Hs_Metabolism_of_amino_acids_and_derivatives_WP1847_52373	0.03248199
Hs_Endothelin_WP2197_56443	0.03644705

^aEarly stage was defined as stage IIa, IIb, IIIa.

lated genes in the recurrence samples included the osteoblast and ossification pathway, the serotonin receptor 2 pathway, various prostate cancer genes and the epidermal growth factor (EGF)-EGFR pathway (Fig. 4A; Table I); while the significant pathways with downregulated genes included the actin cytoskeleton pathway, the G protein pathway, the inflammatory response pathway and the insulin synthesis pathway (Table II).

Metastasis-associated gene expression in early stage recurrent TNBC. Since metastasis is a mechanism associated with tumor recurrence in TNBC, a subset of overexpressed genes were identified in tumor samples obtained from the patients with early stage (IIa, IIb or IIIa) TNBC, who had undergone subsequent tumor recurrence. These included genes encoding MMPs, genes involved in cancer cell migration (CDH2) and genes involved in cell adhesion/motility (KRAS, CDC42, RAC1, ICAM and SRGAP2) (Fig. 4B). Notably, genes associated with tumor stemness and angiogenesis were not overexpressed in these tumor samples.

Significant pathways in stage IIIc recurrent TNBC associated with upregulated and downregulated genes. In contrast to the observations for early recurrence, the significant pathways involving upregulated genes present in stage IIIc recurrence samples included the WNT signaling pathway, glycogen metabolism pathway, integrated pancreatic cancer pathway, mitogen-activated protein kinase (MAPK) cascade pathway, brain-derived neurotrophic factor (BDNF) signaling pathway and prostaglandin synthesis pathway (Table III), while the




Figure 3. Reverse transcription-quantitative polymerase chain reaction for validation of the gene expression profiles. Subsequent to extracting total RNA from the tumors, complementary DNA was created using a First Strand cDNA Synthesis kit. Gene expression assays were then used to validate the differential mRNA expression levels of various identified genes, including (A) MMP9 and (B) SERPINE1 in the recurrent and non-recurrent triple-negative breast cancer samples. MMP9, matrix metalloproteinase 9.

Table III. Significant pathways associated with upregulated genes in stage IIIc recurrent triple-negative breast cancer.

Pathway	P-value
Hs_Factors_involved_in_megakaryocyte_development_and_platelet_production_WP1815_42038	8.41E-05
Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_54212	0.00149959
Hs_Wnt_Signaling_Pathway_WP428_45008	0.00162369
Hs_Nuclear_receptors_in_lipid_metabolism_and_toxicity_WP299_45336	0.00262814
Hs_Glycogen_Metabolism_WP500_45329	0.00337628
Hs_G13_Signaling_Pathway_WP524_45304	0.00365162
Hs_Integrated_Pancreatic_Cancer_Pathway_WP2256_54274	0.00683842
Hs_Integrated_Pancreatic_Cancer_Pathway_WP2377_56677	0.00683842
Hs_G_Protein_Signaling_Pathways_WP35_45294	0.00755248
Hs_Calcium_Regulation_in_the_Cardiac_Cell_WP536_44983	0.00855703
Hs_Synaptic_Vesicle_Pathway_WP2267_56444	0.00898066
Hs_Eicosanoid_Synthesis_WP167_45234	0.01199396
Hs_Muscle_contraction_WP1864_44927	0.01665074
Hs_MAPK_Cascade_WP422_44889	0.02439614
Hs_Prostaglandin_Synthesis_and_Regulation_WP98_45273	0.02763810
Hs_BDNF_signaling_pathway_WP2380_54595	0.03042269
Hs_Endothelin_WP2197_56443	0.03104245
Hs_Vitamin_A_and_carotenoid_metabolism_WP716_52902	0.04216790
Hs_DNA_damage_response_(only_ATM_dependent)_WP710_46091	0.04453868

Table IV. Significant pathways associated with downregulated genes in stage IIIc recurrent triple-negative breast cancer.

Pathway	P-value
Hs_Inflammatory_Response_Pathway_WP453_41201	2.37E-04
Hs_Synaptic_Vesicle_Pathway_WP2267_56444	9.45E-04
Hs_GPCRs_Class_C_Metabotropic_glutamate_pheromone_WP501_45341	0.00142081
Hs_AMPK_signaling_WP1403_44950	0.00217159
Hs_Transport_of_inorganic_cations-anions_and_amino_acids-oligopeptides_WP1936_45061	0.00530772
Hs_Binding_of_RNA_by_Insulin-like_Growth_Factor-2_mRNA_Binding_Proteins_f(IGF2BPs-IMPs-VICKZs)_WP1789_44977	0.01120121
Hs_IL-2_Signaling_pathway_WP49_48400	0.01140687
Hs_BDNF_signaling_pathway_WP2380_54595	0.01594213
Hs_Regulation_of_Actin_Cytoskeleton_WP51_49262	0.01748728
Hs_Calcium_Regulation_in_the_Cardiac_Cell_WP536_44983	0.01878150
Hs_GPCR_downstream_signaling_WP1824_42047	0.02959318
Hs_Arrhythmogenic_right_ventricular_cardiomyopathy_WP2118_47057	0.03163952
Hs_Focal_Adhesion_WP306_45270	0.03231586
Hs_Peroxisomal_lipid_metabolism_WP1878_45246	0.03323053
Hs_RalA_downstream_regulated_genes_WP2290_53118	0.03323053
Hs_Integrated_Pancreatic_Cancer_Pathway_WP2256_54274	0.03932082
Hs_Integrated_Pancreatic_Cancer_Pathway_WP2377_56677	0.03932082
Hs_BMP_signalling_and_regulation_WP1425_44981	0.04406138
Hs_Neurotransmitter_Release_Cycle_WP1871_42089	0.04406138

significant pathways involving downregulated genes in the stage IIIc recurrence samples included the AMPK signaling pathway, interleukin (IL)-2 signaling pathway and BDNF signaling pathway (Table IV).

Stemness-associated gene expression in stage IIIc recurrent TNBC. Since cancer stemness involves self-renewal ability and aggressive behavior, it was not unexpected that a subset of overexpressed stemness genes, including CD44, WNT 4




Figure 4. Heat map representation of (A) pathway- and (B) metastasis-associated upregulated genes in early stage recurrent triple-negative breast cancer. Each row represents a gene and each column represents a patient. Early stage is defined as stages IIa, IIb and IIIa. Red indicates upregulation, green indicates downregulation and black indicates no change. The yellow box indicates genes that are upregulated in tumors with subsequent recurrence compared to those without. The expression ratios ranged between -3 and 3 on a log scale.




Figure 5. Heat map representation of (A) stemness-associated and (B) angiogenesis-associated upregulated genes in stage IIIc recurrent triple-negative breast cancer. Each row represents a gene and each column represents a patient. Red indicates upregulation, green indicates downregulation and black indicates no change. The yellow box indicates genes that are upregulated in tumors with subsequent recurrence compared to those without. The expression ratios ranged between -3 and 3 on a log scale.




Figure 6. Pathway network analyses of upregulated genes from early stage (stages II and IIIa) TNBC. Arrow direction indicates a functional association between an upstream regulator and a downstream element. The results demonstrated that there were significant pathway networks involving *CDK1* and *STAT1*, regulating cell growth of early stage TNBC tumors. TNBC, triple-negative breast cancer.




Figure 7. Pathway network analyses on upregulated genes from late stage (stage IIIc) TNBC. Arrow direction indicates a functional association between an upstream regulator and a downstream element. The results demonstrated that there were significant pathway networks involving *PTGS*, *RAS* and *WNT*, promoting angiogenesis and stemness of late stage TNBC tumors. TNBC, triple-negative breast cancer.

and WNT 16, were identified in tumor samples obtained from patients with late stage (IIIc) TNBC and subsequent recurrence (Fig. 5A). In addition, a gene set associated with angiogenesis (Fig. 5B), but not metastasis, was to be overexpressed in these tumor samples.

Functional pathway analysis. In order to elucidate the possible networks involving the pathways identified in the present study, the above-mentioned upregulated and downregulated genes in the early stage and stage IIIc tumor samples were investigated using ingenuity pathway analysis. The network shown in Fig 6 represents the significant pathway network incorporating *CDK1* and *STAT1*, which regulated cell growth

in the early stage TNBC tumor samples. By contrast, Fig. 7 shows the significant pathway network incorporating *PTGS*, *RAS* and *WNT*, which promoted angiogenesis and stemness in the late stage TNBC tumors.

Discussion

It has been suggested that TNBC is not a complete proxy for basal-like breast cancer. Although an appreciation of the significance of basal-like breast cancers predates gene-expression investigations by a number of years, this term was not in widespread use until later (14,15). Several of the most well-known genes associated with basal-like

breast cancer, including keratin 5 and keratin 17, do not differ significantly different between caucasian and Asian populations (16). This observation is contradictory to the fact that the epidemiology and prognosis of breast cancer between different ethnicities is generally reported to be different (17). There is no internationally accepted definition of these tumors. However, the majority of basal-like cancers are also TNBCs, and the majority of cases of TNBC (~80%) are also cases of basal-like breast cancer; therefore, it has been suggested that the triple-negative phenotype and the basal-like phenotype are effectively synonymous (15,16). However, clinical, microarray and immunohistochemical observations have demonstrated that this is not the case (18). The present study enrolled TNBC cases with ER (<1%), PR (<1%) and non amplified HER2. Furthermore, in the present study, the gene expression levels of basal-like breast cancer specific genes, including keratin 5 and keratin 17, were not uniquely upregulated, which was in agreement with those previously reported in Asian TNBC patients (16), indicating that these types of cancer do not possess basal-like breast cancer characteristics.

Compared with previous study designs that used tumor and non-tumor samples for TNBC analysis, the present study was the first, to the best of our knowledge, to focus on the analysis of paired recurrent, vs. non-recurrent TNBC samples. Therefore, the design of the present study was likely to identify potentially important biomarkers and therapeutic targets for the treatment and prevention of TNBC recurrence. It was hypothesized that the TNBC population is heterogeneous and that various subgroups will exhibit different, and possibly specific, expression signatures. The identification of such signatures offers potential perspective into the individualized treatment protocols that are available. These signaling pathways are also likely to be involved in the upregulation of metastatic and/or cancer cell self-renewal genes, leading to higher levels of metastatic activity and resulting in the recurrence of TNBC.

TNBC is a highly diverse type of cancer, and subtyping of TNBC tumors is necessary in order to identify appropriate molecular-based therapies. Evolving technologies are permitting increasing quantities of molecular data to be obtained from tumor tissues, which enable the development of more personalized treatment strategies (19). In this context, whether all basal-like cancers are enriched with cancer stem cells or whether they have a disproportionately high content of cells undergoing epithelial-to-mesenchymal transition (EMT) remains to be elucidated (20). In the present study, which focused on the molecular mechanisms in paired specimens obtained from patients with and without recurrence, the results suggested that the significant pathways involving upregulated genes that are present in stage IIIc recurrent samples included the WNT, glycogen metabolism, integrated pancreatic cancer, MAPK cascade, BDNF and prostaglandin signaling pathways. In addition, the presence of overexpressed stemness genes, including CD44, WNT 4 and WNT 16, were also identified. By contrast, a different subset of overexpressed genes, which included genes encoding MMPs, and genes involved in the cancer cell migration (CDH2) pathway, cell adhesion or motility (KRAS, CDC42, RAC1, ICAM and SRGAP2) and EMT (TWIST1), were identified in the tumor samples obtained from patients with early (stage IIa, IIb, IIIa) tumors. These observations may be useful for biomarker

selection, drug discovery and clinical trial design, all of which may assist in the identification of appropriate targeted therapies for patients with TNBC (13).

Kuo *et al* (13) reported that deregulated genes within the transforming growth factor (TGF)- β signaling pathway were markedly involved in the distant recurrence of TNBC (13). The overexpression of TGF- β 1 has been observed to be mediated by two upstream regulators, tumor necrosis factor and IL-1 β , which are known mediators of the immune/inflammatory response; furthermore, TGF- β 1 itself is crucial to the regulation of T cell-mediated immunity (21). In the present study, similar deregulation of the inflammatory response pathway and the IL-2 signaling pathway were observed in the samples from patients with stage IIIc TNBC recurrence. Taken together, these findings suggested that the distant metastatic invasion of TNBC may be induced by immune/inflammatory deregulation.

According to the St Gallen consensus for chemotherapy guidelines (22), all triple-negative patients are recommended to receive adjuvant systemic chemotherapy in combination of anthracycline-based regimens with taxanes, however, this approach often results in serious side effects in patients. A number of pathway-targeted agents, including EGFR inhibitors, DNA repair pathway inhibitors and anti-angiogenic agents, have been used in clinical trials as targeted therapies for TNBC (7,23). These may be used, alongside traditional chemotherapy treatments, to treat triple-negative patients with an unfavorable prognosis. The gene profiling in the current study may provide a prognostic predictor and, thus may become a clinically useful tool for the identification of triple-negative patients who are at low risk of recurrence. The subsequent provision of moderate doses of combined regimens, or the anthracycline-based regimens alone, in these patients can be offered to reduce patient side effects. Among the stage IIIc recurrence group, the prostaglandin synthesis and regulation signaling pathway exhibited significant alterations in expression. COX-2, an inducible form of cyclooxygenase, is the rate limiting step in the production of prostaglandins, which has been suggested to be involved in long-term inflammation and the promotion of cancer growth. Therefore, the results of the present study suggest that this pathway is likely to be important in the late stages of tumor growth and metastasis.

Acknowledgements

The present study was supported, in part, by the Division of Experimental Surgery of the Department of Surgery, Taipei Veterans General Hospital (Taiwan, China; grant no. 101DHA0100010) and the Ministry of Health and Welfare (Center of Excellence for Cancer Research at Taipei Veterans General Hospital Phase II; MOHW103-TD-B-111-02).

References

1. Lin YS, Jen YM, Wang BB, Lee JC and Kang BH: Epidemiology of oral cavity cancer in taiwan with emphasis on the role of betel nut chewing. *ORL J Otorhinolaryngol Relat Spec* 67: 230-236, 2005.
2. DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. *CA Cancer J Clin* 61: 409-418, 2011.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 235: 177-182, 1987.

4. Gradishar WJ: Tamoxifen-what next? *Oncologist* 9: 378-384, 2004.
5. Yamamoto Y and Iwase H: Clinicopathological features and treatment strategy for triple-negative breast cancer. *Int J Clin Oncol* 15: 341-351, 2010.
6. Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, *et al*: Triple-negative breast cancer: Present challenges and new perspectives. *Mol Oncol* 4: 209-229, 2010.
7. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM and Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. *N Engl J Med* 364: 205-214, 2011.
8. Perou CM, Sørli T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, *et al*: Molecular portraits of human breast tumours. *Nature* 406: 747-752, 2000.
9. Mohamed A, Krajewski K, Cakar B and Ma CX: Targeted therapy for breast cancer. *Am J Pathol* 183: 1096-1112, 2013.
10. Thike AA, Yong-Zheng Chong L, Cheok PY, Li HH, Wai-Cheong Yip G, Huat Bay B, Tse GM, Iqbal J, and Tan PH: Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. *Mod Pathol* 27: 352-360, 2014.
11. Chen LH, Kuo WH, Tsai MH, Chen PC, Hsiao CK, Chuang EY, Chang LY, Hsieh FJ, Lai LC and Chang KJ: Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan. *PLoS One* 6: e28222, 2011.
12. Hicks C, Kumar R, Pannuti A, Backus K, Brown A, Monico J and Miele L: An integrative genomics approach for associating GWAS information with triple-negative breast cancer. *Cancer Inform* 12: 1-20, 2013.
13. Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ and Chuang EY: Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: A clinical study of triple-negative breast carcinomas. *PLoS One* 7: e45831, 2012.
14. Sotiriou C and Pusztai L: Gene-expression signatures in breast cancer. *N Engl J Med* 360: 790-800, 2009.
15. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, and van de Vijver MJ: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. *Breast Cancer Res* 9: R65, 2007.
16. Peppercorn J, Perou CM and Carey LA: Molecular subtypes in breast cancer evaluation and management: divide and conquer. *Cancer Invest* 26: 1-10, 2008.
17. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, Kinoshita T, Takei H, Takahashi K, Ikeda M, *et al*: The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. *Breast* 16 (Suppl 2): S72-S77, 2007.
18. Weigelt B, Baehner FL and Reis-Filho JS: The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: A retrospective of the last decade. *J Pathol* 220: 263-280, 2010.
19. Rodenhiser DI, Andrews JD, Vandenberg TA and Chambers AF: Gene signatures of breast cancer progression and metastasis. *Breast Cancer Res* 13: 201, 2011.
20. Zavadil J and Böttlinger EP: TGF-beta and epithelial-to-mesenchymal transitions. *Oncogene* 24: 5764-5774, 2005.
21. Liu Y, Teige I, Birnir B and Issazadeh-Navikas S: Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. *Nat Med* 12: 518-525, 2006.
22. Untch M, Gerber B, Harbeck N, *et al*: 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013). *Breast Care (Basel)* 8: 221-229, 2013.
23. Hudis CA and Gianni L: Triple-negative breast cancer: An unmet medical need. *Oncologist* 16 (Suppl 1): 1-11, 2011.